

# Marked improvement of oral intake with nivolumab monotherapy in a patient with microsatellite instability-high gastric cancer with insufficient oral intake

Takatsugu Ogata<sup>1</sup>, Yukiya Narita<sup>1</sup>, Kazunari Misawa<sup>1</sup>, Waki Hosoda<sup>1</sup>, and Kei Muro<sup>1</sup>

<sup>1</sup>Aichi Cancer Center Hospital

May 21, 2020

## Abstract

This is the first report of marked improvement of oral intake by third-line nivolumab monotherapy in a gastric cancer patient with insufficient oral intake and European Cooperative Oncology Group performance status 2. We should consider immune checkpoint inhibitors for microsatellite instability-high gastric cancer, regardless of the patient's general condition.

## Hosted file

Marked\_improvement\_of\_oral\_intake\_ver2.0\_CCR3.doc available at <https://authorea.com/users/324752/articles/452868-marked-improvement-of-oral-intake-with-nivolumab-monotherapy-in-a-patient-with-microsatellite-instability-high-gastric-cancer-with-insufficient-oral-intake>



